PTGER3抗体;PTGER3 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12524(PTGER3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P12524(PTGER3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The PTGER3 antibody targets the prostaglandin E receptor 3 (PTGER3 or EP3), a G protein-coupled receptor that binds prostaglandin E2 (PGE2), a lipid mediator involved in inflammation, pain, and various physiological processes. PTGER3 is encoded by the *PTGER3* gene and exists as multiple splice variants, enabling diverse signaling pathways (e.g., Gi, Gs, or Gq coupling) depending on tissue context. It plays roles in regulating vascular tone, immune responses, and gastrointestinal functions, and has been implicated in pathological conditions such as cancer, cardiovascular diseases, and chronic inflammation.

PTGER3 antibodies are essential tools for research, enabling detection and localization of the receptor in cells and tissues via techniques like Western blotting, immunohistochemistry, or flow cytometry. They help elucidate PTGER3's expression patterns, signaling mechanisms, and interactions in disease models. Therapeutic applications are explored in preclinical studies, particularly in targeting PTGER3 to modulate PGE2-mediated pathways in cancer progression or inflammatory disorders. However, challenges remain in developing isoform-specific antibodies due to the receptor's splice variant complexity. Current research focuses on clarifying PTGER3's dual pro- and anti-inflammatory roles and its potential as a biomarker or drug target.